Related references
Note: Only part of the references are listed.Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
Sonia A. Patel et al.
CLINICAL CANCER RESEARCH (2023)
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review
Lauren R. Schaff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)
Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterations
Andrea Franza et al.
FUTURE ONCOLOGY (2022)
Infigratinib for cholangiocarcinoma
Saeed Sadeghi
DRUGS OF TODAY (2022)
Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs
Hanna Cho et al.
FRONTIERS IN ONCOLOGY (2021)
Evolving role of regorafenib for the treatment of advanced cancers
Axel Grothey et al.
CANCER TREATMENT REVIEWS (2020)
Tumor Cell Invasion in Glioblastoma
Arabel Vollmann-Zwerenz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma
Bhavesh K. Ahir et al.
MOLECULAR NEUROBIOLOGY (2020)
Design, Synthesis, and Biological Evaluation of Covalent Inhibitors of Focal Adhesion Kinase (FAK) against Human Malignant Glioblastoma
Bo Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Alpha6-Integrin Regulates FGFR1 Expression through the ZEB1/YAP1 Transcription Complex in Glioblastoma Stem Cells Resulting in Enhanced Proliferation and Stemness
Aline Kowalski-Chauvel et al.
CANCERS (2019)
Trends and Challenges in Tumor Anti-Angiogenic Therapies
Jozsef Jaszai et al.
CELLS (2019)
C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis
Zhuo Chen et al.
ACTA PHARMACOLOGICA SINICA (2019)
Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis
Guy A. Conlon et al.
JOURNAL OF PATHOLOGY (2019)
Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway
Yoshiro Itatani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Drug review: Pazopanib
Shingo Miyamoto et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Dianhydrogalactitol, a potential multitarget agent, inhibits glioblastoma migration, invasion, and angiogenesis
Xia Jiang et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents
Wenbo Zhou et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
FGF Receptors: Cancer Biology and Therapeutics
Masaru Katoh et al.
MEDICINAL RESEARCH REVIEWS (2014)
Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cyanoacetamide MCR (III): Three-Component Gewald Reactions Revisited
Kan Wang et al.
JOURNAL OF COMBINATORIAL CHEMISTRY (2010)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line
Junya Fukai et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas
V Rand et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
JM Fang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
